Analysts Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00

Shares of Agenus Inc. (NASDAQ:AGEN) have earned an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Wednesday, January 22nd.

Agenus Trading Down 6.6 %

AGEN opened at $2.41 on Friday. Agenus has a 12-month low of $2.37 and a 12-month high of $19.69. The company has a market cap of $56.54 million, a price-to-earnings ratio of -0.21 and a beta of 1.31. The company’s 50 day moving average is $3.29 and its 200 day moving average is $3.95.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently made changes to their positions in AGEN. B. Riley Financial Inc. purchased a new position in Agenus in the 4th quarter worth $2,074,000. Geode Capital Management LLC grew its position in Agenus by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the period. State Street Corp grew its position in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the period. Gilead Sciences Inc. acquired a new stake in Agenus during the 4th quarter worth about $635,000. Finally, Northern Trust Corp grew its position in Agenus by 14.8% during the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company’s stock worth $572,000 after purchasing an additional 26,870 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.